Efficacy of simvastatin in plaque psoriasis: A pilot study

Slides:

Advertisements

Similar presentations

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

Advertisements

Optimal time to provide skin cancer and photoprotection education to pediatric solid organ transplant recipients Lily Chen, BA, Feng Gao, MD, PhD, MPH,

Lauren Kwa, BA, Jonathan I. Silverberg, MD, PhD, MPH

A girl with a solitary red bulla

A randomized controlled crossover trial: Lidocaine injected at a 90-degree angle causes less pain than lidocaine injected at a 45-degree angle Kathryn.

Yul W. Yang, MD, PhD, David J. DiCaudo, MD

Psoriasis: Latitude does make a difference

Cutaneous myiasis associated with scalp psoriasis

Baldness reversed by chemotherapy

Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD

Ahmad Al Aboud, MD, Melissa Abrams, MD, Anthony J. Mancini, MD

Serum leptin and adiponectin levels in atopic dermatitis (AD) and their relation to disease severity Byeol Han, MD, Wen Hao Wu, PhD, Jung Min Bae, MD,

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD

Sarah Sung, MD, Alexa B. Kimball, MD, MPH

Deficiency of serum concentration of 25-hydroxyvitamin D correlates with severity of disease in chronic plaque psoriasis Federica Ricceri, MD, Leonardo.

Surveillance and assessment of occupational dermatitis using Rhode Island workers' compensation data 1998 to 2002 Irwin B. Horwitz, PhD, Brian P. McCall,

Vaishali Patel, PharmD, Elizabeth J. Horn, PhD, Steve J

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the treatment of patients with moderate to.

The impact of secukinumab treatment on the prevalence of human papillomavirus in patients with psoriasis: A pilot study Hsien-Yi Chiu, MD, Tsen-Fang.

Pediatric teledermatology: Observations based on 429 consults

Clindamycin-induced Sweet syndrome

JAK inhibitors in dermatology: The promise of a new drug class

The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis Alan Menter, MD, Jennifer C. Cather, MD, Diane.

Assessing adherence with phototherapy protocols

Effect of appearance-based education compared with health-based education on sunscreen use and knowledge: A randomized controlled trial William Tuong,

Pharmacy costs of specialty medications for plaque psoriasis in the United States Eric J. Yang, BS, Kristen M. Beck, MD, Sahil Sekhon, MD, Tina Bhutani,

Smoking and risk of psoriasis: A nationwide cohort study

Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial Diamant.

A pilot trial of treprostinil for the treatment and prevention of digital ulcers in patients with systemic sclerosis Lorinda Chung, MD, David Fiorentino,

Effect of psoriatic arthritis on ixekizumab clinical outcomes in moderate-to-severe psoriasis patients: A post hoc analysis Alice B. Gottlieb, MD, PhD,

Pilot study of a skin cancer education curriculum for medical students

Applying for dermatology residency is difficult and expensive

Infliximab treatment for severe psoriasis in a patient with active hepatitis B virus infection Alberto Conde-Taboada, MD, Javier Pedraz Muñoz, MD, Lucía.

Seasonal variation of acne and psoriasis: A 3-year study using the Physician Global Assessment severity scale Vanessa Lindsay Pascoe, MD, Alexandra Boer.

Google search trends for tanning salons: Temporal patterns indicate peak interest in mid spring Derek D. Reed, PhD, BCBA-D Journal of the American Academy.

A survey-based study on nail examinations at an American Academy of Dermatology free skin cancer screening Dayoung Ko, BS, Shari R. Lipner, MD, PhD

Treatment of psoriasis vulgaris using low-dose naltrexone

Loss of efficacy of secukinumab for psoriasis at 24 to 32 weeks

Infectious rash after riding elephants

Lip edema Journal of the American Academy of Dermatology

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with difficult-to-treat nail and scalp psoriasis: Results of 2 phase III randomized, controlled.

Pooja H. Rambhia, BA, Ivan J. Stojanov, DMD, Joshua Arbesman, MD

Hugh Gloster, MD, Chesahna Kindred, MBA

Seasonal patterns in alopecia areata, totalis, and universalis

Appearance of lentigines in psoriasis patients treated with apremilast

Medicaid acceptance among pediatric dermatologists

Pruritus severity in patients with psoriasis is not correlated with psoriasis disease severity David Roblin, MD, FRCP, Ro Wickramasinghe, PhD, MBA, Gil.

Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with.

Penile calciphylaxis Journal of the American Academy of Dermatology

Alopecia areata is associated with impaired health-related quality of life: A survey of affected adults and children and their families Lucy Y. Liu,

Jennifer L. Hundley, MD, Christie L

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Modification of the nail psoriasis severity index

Tofacitinib therapy for children with severe alopecia areata

Digital photography in the diagnosis of scabies

A simple algorithm for evaluating dermatologic disease in critically ill patients: A study based on retrospective review of medical intensive care unit.

An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis James Krell, MD, FAAD, Candi Nelson, BS,

Eyebrow transplantation: Alternative body sites as a donor source

Gaps in pain management in dermatology: A needs assessment from Canada

Classification of facial psoriasis based on the distributions of facial lesions Seung Man Woo, MD, Jung Won Choi, MD, Hyun Sun Yoon, MD, Seong Jin Jo,

Numerous hyperpigmented macules of the oral mucosa

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Lisa A. Beck, MD, Sarbjit Saini, MD

Randomized study of topical tacrolimus ointment as possible treatment for resistant idiopathic pruritus ani Erwin Suys, MD Journal of the American Academy.

“Boot foot” with pseudomonas colonization

Apremilast, an oral phosphodiesterase-4 inhibitor, in the treatment of palmoplantar psoriasis: Results of a pooled analysis from phase II PSOR-005 and.

Anastasia O. Kurta, DO, Daisy Dai, PhD, Eric S

Stuart M. Goldsmith, MD, Armand B. Cognetta, MD

Brodalumab in the treatment of moderate to severe psoriasis in patients when previous anti-interleukin 17A therapies have failed Grace Kimmel, MD, Margot.

Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: Results through 108 weeks of a randomized, controlled phase.

Presentation transcript:

Efficacy of simvastatin in plaque psoriasis: A pilot study Ivan Valeryevich Shirinsky, MD, PhD, Valery Stepanovich Shirinsky, MD, PhD Journal of the American Academy of Dermatology Volume 57, Issue 3, Pages 529-531 (September 2007) DOI: 10.1016/j.jaad.2007.05.040 Copyright © 2007 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 Changes in evaluated parameters form beginning (“week 0”) to end of simvastatin therapy (“week 8”). Y-axes show PASI score (A); DLQI (B); 5-point physician's overall assessment of disease (integer scale 0-5) (C). Level of significance was measured using Wilcoxon signed-rank test. Journal of the American Academy of Dermatology 2007 57, 529-531DOI: (10.1016/j.jaad.2007.05.040) Copyright © 2007 American Academy of Dermatology, Inc. Terms and Conditions